Diligence memo · auto-generated · as of July 2, 2026
Scilex Pharmaceuticals Inc.
Scilex Pharmaceuticals Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Scilex Pharmaceuticals Inc. operates in Pharmaceuticals, based in MALVERN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Scilex Pharmaceuticals Inc. has raised $13M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on —.
Most recent recorded round closed around 2016-05-04.
Valuation (modeled)modeled
Provath models Scilex Pharmaceuticals Inc. at approximately $15M (range $550K–$81M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.08× the median modeled value of Series A Pharmaceuticals companies in 2016–2018 (88 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 139 months.
Last raise 10.2 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 4.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 59% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 23% of those peers.
Closest niche peers: Arbutus Biopharma Corp, Rvc 360, Llc, Sterrx, Llc, Ribometrix, Inc., Neuraltus Pharmaceuticals, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.